Radius Health Inc  

(Public, NASDAQ:RDUS)   Watch this stock  
Find more results for William David Ward, II�
45.02
+0.39 (0.87%)
After Hours: 45.00 -0.02 (-0.04%)
Jul 26, 7:59PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 44.09 - 45.93
52 week 24.75 - 79.90
Open 44.33
Vol / Avg. 348,533.00/545,746.00
Mkt cap 1.91B
P/E     -
Div/yield     -
EPS -3.00
Shares 43.04M
Beta     -
Inst. own 99%
Aug 4, 2016
Q2 2016 Radius Health Inc Earnings Release - 9:30AM EDT - Add to calendar
Aug 4, 2016
Q2 2016 Radius Health Inc Earnings Call - 8:00AM EDT - Add to calendar
Jul 12, 2016
Radius Health Inc at Cantor Fitzgerald Healthcare Conference
Jun 7, 2016
Radius Health Inc at Goldman Sachs Global Healthcare Conference
May 5, 2016
Q1 2016 Radius Health Inc Earnings Release
May 5, 2016
Q1 2016 Radius Health Inc Earnings Call - Webcast
May 4, 2016
Radius Health Inc at Deutsche Bank Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -34.99% -34.36%
Return on average equity -36.58% -38.70%
Employees 73 -
CDP Score - -

Address

950 Winter St
WALTHAM, MA 02451-1424
United States - Map
+1-617-5514000 (Phone)
+1-617-5514701 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Radius Health, Inc. is a science-driven biopharmaceutical company focused on developing therapeutics for patients with osteoporosis, oncology and endocrine diseases. The Company's lead product candidate is the investigational drug abaloparatide for subcutaneous injection (abaloparatide-SC), which has completed Phase III development for potential use in the reduction of fracture risk in postmenopausal women with osteoporosis. Its abaloparatide-SC is under regulatory review in Europe. Its clinical pipeline also includes an investigational abaloparatide transdermal patch for potential use in osteoporosis, and the investigational drug RAD1901 for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Its preclinical pipeline includes RAD140, which is an orally bioavailable non-steroidal, selective androgen receptor modulator (SARM). RAD140 is under investigation for potential applications in oncology and multiple conditions.

Officers and directors

Kurt C. Graves Independent Chairman of the Board
Age: 48
Bio & Compensation  - Reuters
Robert E. Ward President, Chief Executive Officer, Director
Age: 58
Bio & Compensation  - Reuters
B. Nicholas Harvey Chief Financial Officer, Senior Vice President, Treasurer, Secretary
Age: 55
Bio & Compensation  - Reuters
Gary Hattersley Ph.D. Senior Vice President, Chief Scientific Officer
Age: 49
Bio & Compensation  - Reuters
Brent Hatzis-Schoch Senior Vice President, General Counsel
Age: 51
Bio & Compensation  - Reuters
Dinesh Purandare Senior Vice President, Head of Global Oncology
Age: 52
Bio & Compensation  - Reuters
Lorraine A. Fitzpatrick M.D. Chief Medical Officer
Age: 61
Bio & Compensation  - Reuters
David P. Snow Chief Commercial Officer
Age: 54
Bio & Compensation  - Reuters
Gregory Williams Ph.D. Chief Development Officer
Age: 56
Bio & Compensation  - Reuters
Catherine J. Friedman Director
Age: 55
Bio & Compensation  - Reuters